|
| ID |
DDInter1577 |
| Drug Type |
small molecule |
| Molecular Formula |
C29H27F2N7O5S |
| Molecular Weight |
623.641
|
| Description |
Relugolix is an oral GnRH receptor antagonist for androgen deprivation therapy in the treatment of advanced prostate cancer.
|
| ATC Classification |
- |
| IUPAC Name |
1-(4-{1-[(2,6-Difluorophenyl)Methyl]-5-[(Dimethylamino)Methyl]-3-(6-Methoxypyridazin-3-Yl)-2,4-Dioxo-1H,2H,3H,4H-Thieno[2,3-D]Py |
| InChI |
Inchi=1S/C29H27F2N7O5S/C1-36(2)14-19-24-26(39)38(22-12-13-23(42-3)34-33-22)29(41)37(15-18-20(30)6-5-7-21(18)31)27(24)44-25(19)16-8-10-17(11-9-16)32-28(40)35-43-4/H5-13H,14-15H2,1-4H3,(H2,32,35,40) |
| InChI Key |
AOMXMOCNKJTRQP-UHFFFAOYSA-N |
| Canonical SMILES |
CONC(=O)NC1=CC=C(C=C1)C1=C(CN(C)C)C2=C(S1)N(CC1=C(F)C=CC=C1F)C(=O)N(C2=O)C1=CC=C(OC)N=N1 |
| Useful Links |
DrugBank
ChEMBL
PubChem
|